Table 1

Clinical characteristics and the use of GTN before PCI in patients with ACS

Total
(n=947)
GTN group
(n=289)
Non-GTN group (n=658)P value
Age (years)71.0 (63.0–80.0)70.0 (62.0–80.0)71.0 (63.0–80.0)0.377
Elderly (≥75 years), n (%)378 (39.9)112 (38.7)266 (40.4)0.629
Male, n (%)678 (71.5)215 (74.3)463 (70.3)0.205
BMI (kg/m2)23.4 (21.4–26.0)23.7 (21.4–26.3)23.4 (21.4–25.8)0.114
Waist circumference (cm)87.0 (82.0–93.0)87.6 (82.0–94.5)87.0 (81.0–93.0)0.102
Systolic blood pressure
(mm Hg)
132.0 (112.0–154.0)132.0 (110.0–143.5)134.0 (112.0–157.0)0.030
Diastolic blood pressure
(mm Hg)
81.0 (68.0–93.2)80.0 (66.0–93.0)83.0 (69.0–94.0)0.081
Previous/current smoking,
n (%)
465 (49.1)139 (48.0)326 (49.5)0.682
Hypertension, n (%)717 (75.7)239 (82.6)478 (72.6)<0.001
Dyslipidaemia, n (%)657 (69.3)222 (76.8)435 (66.1)<0.001
Diabetes mellitus, n (%)300 (31.6)100 (34.6)200 (30.3)0.200
Metabolic syndrome, n (%)330 (34.8)97 (33.5)233 (35.4)0.348
Haemodialysis, n (%)29 (3.0)10 (3.4)19 (2.8)0.638
TG (mg/L)106.0 (73.0–159.0)104.0 (73.0–149.0)106.0 (73.0–164.5)0.410
HDL-C (mg/L)48.0 (40.7–58.0)48.0 (41.0–59.0)48.0 (40.0–57.0)0.211
LDL-C (mg/L)121.0 (98.0–154.0)123.0 (97.0–151.0)121.0 (98.0–148.0)0.604
HbA1c (%)5.90 (5.50–6.50)6.00 (5.60–6.60)5.90 (5.50–6.40)0.064
eGFR (mL/min per 1.73 m2)61.4 (48.4–72.8)62.0 (47.6–73.2)61.2 (48.5–72.6)0.932
LVEF (%)56.8 (49.0–62.3)56.1 (50.0–62.4)56.8 (48.8–62.3)0.924
STEMI, n (%)748 (78.9)226 (78.2)522 (76.2)0.694
MACE, n (%)146 (15.4)56 (19.3)90 (13.6)0.025
 All-cause death, n (%)88 (9.2)34 (11.7)54 (8.2)0.082
 MI, n (%)13 (1.3)4 (1.3)9 (1.3)0.984
 Stroke, n (%)23 (2.4)9 (3.1)14 (2.1)0.364
 Heart failure, n (%)27 (2.8)11 (3.8)16 (2.4)0.242
TLR, n (%)51 (5.3)21 (7.2)30 (4.5)0.089
  • Data are presented as medians (IQRs) or numbers (percentages). Bold values indicate statistical significance at the p <0.05 level.

  • ACS, acute coronary syndrome; BMI, body mass index; eGFR, estimated glomerular filtration rate; GTN, nitroglycerin; HbA1c, hemoglobin A1c ; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction; MACE, major adverse cardiovascular event; MI, myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; TG, triglyceride; TLR, target lesion revascularisation.